0001437749-26-017142
SEC filingQ1 2026 losses deepened to -$6.2M operating income and -$5.0M free cash burn from prior year, driven by CDMO ramp-up costs and debt servicing amid strategic biopharma investments and liquidity constraints.
Tivic Health Systems reported significantly wider losses in Q1 FY2026, with operating income at -$5.6 million versus -$1.5 million in the prior year quarter, a -274% YoY change. This deterioration stems from heavy investments in the company's CDMO operations, which encompass facility costs and equipment rentals alongside headcount and professional fees as detailed in management discussion. These expenses reflect the ramp-up of the San Antonio facility, positioning Tivic for a biopharma services pivot amid persistent unprofitability.
Net income followed suit, reaching -$6.2 million compared to -$1.5 million YoY (-313%), exacerbated by higher interest expense and amortization of debt discount and issuance costs on the senior convertible note payable. While diluted EPS showed relative improvement to -$2.23 from -$2.52 (11.5% YoY better), this was due to share count expansion diluting the per-share burden of amplified losses, not underlying profitability gains.
Management highlights ongoing risks, expecting substantial additional operating losses to support pre-clinical and clinical trials, new product development or acquisitions, regulatory approvals, commercialization, and R&D programs. Liquidity needs are acute, with plans to raise capital for these operations and potential collaborations whose timing and impact remain uncertain. External factors like tariffs on imports from China or Canada could further pressure gross margins. A decrease in orders could also delay future revenues, amplifying cash burn implications in this high-investment phase.